Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Prenatal Genetic Diagnosis Laboratory, |
RCV004821343 | SCV005068324 | pathogenic | Al-Gazali syndrome; Spondyloepimetaphyseal dysplasia with joint laxity, type 1, with or without fractures; Ehlers-Danlos syndrome, spondylodysplastic type, 2 | 2024-06-26 | criteria provided, single submitter | clinical testing | This sequence change affects methionine residue at the initiation codon of the B3GALT6 mRNA (p.Met1?). Different varaints disrupting the initiator codon of B3GALT6 gene have been reported in multiple unrelated patients with Spondyloepimetaphyseal dysplasia with joint laxity (PMID: 23664117, ClinVar ID: 1067539, 1452181, 2151860). The same location with a different neucleotide change affecting the initiation codon, c.1A>G (p.Met1?), has been reported in four Japanese families with Spondyloepimetaphyseal dysplasia with joint laxity (PMID: 23664117). Functional study demonstrated the mutant B3GALT6 protein with c.1A>G had a molecular weight ~4 kD lower compared with the wildtype protein, suggesting the mutation in the initiation codon probably resulted in an N-terminal deletion of 41 amino acids (PMID: 23664117). The c.1A>C variant is currently not reported in any pateints nor in the gnomAD database (v2.1.1). Therefore, it is interpreted as pathogenic according to ACMG/AMP guidelines. |